CN106596642A - Hydrophobic modification based blood coagulation sensor, preparation method and application thereof - Google Patents
Hydrophobic modification based blood coagulation sensor, preparation method and application thereof Download PDFInfo
- Publication number
- CN106596642A CN106596642A CN201611112697.7A CN201611112697A CN106596642A CN 106596642 A CN106596642 A CN 106596642A CN 201611112697 A CN201611112697 A CN 201611112697A CN 106596642 A CN106596642 A CN 106596642A
- Authority
- CN
- China
- Prior art keywords
- sensor
- detection
- coagulation
- hydrophobic
- piezoelectric film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 28
- 230000023555 blood coagulation Effects 0.000 title claims description 16
- 230000004048 modification Effects 0.000 title abstract description 10
- 238000012986 modification Methods 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 238000001514 detection method Methods 0.000 claims abstract description 55
- 230000015271 coagulation Effects 0.000 claims abstract description 25
- 238000005345 coagulation Methods 0.000 claims abstract description 25
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000007738 vacuum evaporation Methods 0.000 claims description 3
- 229920000052 poly(p-xylylene) Polymers 0.000 abstract description 21
- 102000009123 Fibrin Human genes 0.000 abstract description 13
- 108010073385 Fibrin Proteins 0.000 abstract description 13
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract description 13
- 229950003499 fibrin Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 4
- 239000007795 chemical reaction product Substances 0.000 abstract description 3
- -1 polyxylylene Polymers 0.000 abstract 1
- 239000010408 film Substances 0.000 description 16
- 230000003287 optical effect Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 5
- 108010000499 Thromboplastin Proteins 0.000 description 5
- 102000002262 Thromboplastin Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本案涉及基于疏水修饰的凝血检测传感器、其制备方法及应用,该凝血检测传感器包括有压电薄膜传感器,在该压电薄膜传感器表面修饰有疏水层,所述疏水层为聚二甲苯。本案将Parylene真空蒸镀到压电薄膜传感器表面,实现表面疏水性的提高,达到了吸附纤维蛋白疏水结构域的效果;降低了对压电传感器的影响,增强传感器表面与凝血终产物纤维蛋白结合能力,实现提高传感器输出信号频率稳定性的效果;此外,本案具有可批量化修饰的特点,有助于消除芯片修饰批间差异性。
This case involves a coagulation detection sensor based on hydrophobic modification, its preparation method and application. The coagulation detection sensor includes a piezoelectric film sensor, and a hydrophobic layer is modified on the surface of the piezoelectric film sensor, and the hydrophobic layer is polyxylylene. In this case, Parylene was vacuum-evaporated onto the surface of the piezoelectric film sensor to improve the hydrophobicity of the surface and achieve the effect of adsorbing the hydrophobic domain of fibrin; it reduced the impact on the piezoelectric sensor and enhanced the binding of the sensor surface to the coagulation end product fibrin ability to achieve the effect of improving the frequency stability of the sensor output signal; in addition, this case has the characteristics of batch modification, which helps to eliminate the difference between batches of chip modification.
Description
技术领域technical field
本发明涉及一种凝血检测传感器,特别涉及一种基于疏水修饰的凝血检测传感器、其制备方法及应用。The invention relates to a coagulation detection sensor, in particular to a hydrophobic modification-based coagulation detection sensor, its preparation method and application.
背景技术Background technique
目前,光学检测方法已广泛应用于凝血检测,检验中最常用的检测指标有凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)、纤维蛋白原(FIB)、凝血酶时间(TT)、内源凝血因子、外源凝血因子、高分子量肝素、低分子量肝素、蛋白C、蛋白S等,检测项目丰富但光学检测对待检样本要求苛刻,检测时间长,存在一定的局限性。光学原理主要是散射比浊法:根据待验样品在凝固过程中散射光的变化来确定检测终点。在该方法中检测通道的单色光源与光探测器呈90°直角,当向样品中加入凝血激活剂后,随样品中纤维蛋白凝块的形成过程,样品的散射光强度逐步增加。当样品完全凝固以后,散射光的强度不再变化,通常是把凝固的起始点作为0%,凝固终点作为100%,把50%作为凝固时间。光探测器接收这一光学的变化,将其转化为电信号,经过放大再被传送到监测器上进行处理,描出凝固曲线,因此,对全血等透光性差的复杂样本进行检测时,光学检测方法无法获得正确检测结果,而基于光学原理搭设光路又很难实现微小化、便携化设备。At present, optical detection methods have been widely used in blood coagulation detection. The most commonly used detection indicators in the test are prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen (FIB), thrombin time (TT). ), endogenous coagulation factors, exogenous coagulation factors, high-molecular-weight heparin, low-molecular-weight heparin, protein C, protein S, etc. There are many detection items, but optical detection has strict requirements on the samples to be tested, and the detection time is long, so there are certain limitations. The optical principle is mainly scattering turbidimetry: the detection end point is determined according to the change of scattered light of the sample to be tested during the solidification process. In this method, the monochromatic light source of the detection channel and the light detector are at a right angle of 90°. When the coagulation activator is added to the sample, the scattered light intensity of the sample gradually increases with the formation of the fibrin clot in the sample. When the sample is completely solidified, the intensity of the scattered light does not change. Usually, the starting point of solidification is regarded as 0%, the end point of solidification is regarded as 100%, and 50% is regarded as the solidification time. The optical detector receives this optical change, converts it into an electrical signal, and then transmits it to the monitor for processing after amplification to draw the coagulation curve. Therefore, when detecting complex samples with poor light transmission such as whole blood, optical The detection method cannot obtain correct detection results, and it is difficult to realize miniaturized and portable equipment by building an optical path based on optical principles.
压电薄膜传感器(QCM)是一种高灵敏度的质量传感器,其检测原理是待测血液由纤维蛋白原转变为纤维蛋白后与薄膜传感器表面结合,产生粘弹性变化引起谐振频率的改变,对表面纳克级质量变化的响应具有灵敏度高、响应速度快等特点。在检测高粘度不透光的复杂样本检测性能优于现有的光学检测手段,压电薄膜传感器与光学凝血仪器相比检测项目少,但可通过多通道实现多指标检测,且检测时间短。另外压电薄膜类传感器有体积小的特点,易于实现小型化设备的开发及生产应用。Piezoelectric film sensor (QCM) is a high-sensitivity mass sensor. Its detection principle is that the blood to be measured changes from fibrinogen to fibrin and combines with the surface of the film sensor to produce viscoelastic changes that cause changes in resonance frequency. The response to nanogram-level mass change has the characteristics of high sensitivity and fast response speed. Compared with the optical coagulation instrument, the piezoelectric film sensor has fewer detection items, but it can realize multi-index detection through multiple channels, and the detection time is short. In addition, the piezoelectric film sensor has the characteristics of small size, which is easy to realize the development and production application of miniaturized equipment.
压电薄膜传感器直接用于血清或全血等复杂样品检测时同样面临样品体系中组分繁杂的问题,大量的非目标蛋白和可溶性成分会造成很大的背景干扰。常规解决方案在传感器表面沉积蛋白A、链霉亲和素和生物素等亲和性蛋白,以此提高特异性抗体或生物分子的结合效率。但抗原抗体结合的方法又需要过长反应时间,无法满足凝血快速检测(3mins内)的要求,aPTT正常值在28s~33s(根据不同试剂变化),而PT正常值在12s~16s。因此本案有必要开发一种全新的凝血检测传感器来既可以提高吸附特异性,又能缩短检测时间。When the piezoelectric film sensor is directly used for the detection of complex samples such as serum or whole blood, it also faces the problem of complicated components in the sample system, and a large number of non-target proteins and soluble components will cause great background interference. Conventional solutions deposit affinity proteins such as protein A, streptavidin, and biotin on the sensor surface to improve the binding efficiency of specific antibodies or biomolecules. However, the method of antigen-antibody combination requires too long reaction time, which cannot meet the requirements of rapid coagulation detection (within 3 minutes). The normal value of aPTT is 28s-33s (varies according to different reagents), and the normal value of PT is 12s-16s. Therefore, it is necessary to develop a new blood coagulation detection sensor in this case to improve the adsorption specificity and shorten the detection time.
发明内容Contents of the invention
针对现有技术中存在的技术问题,本案提供一种基于疏水修饰的凝血检测传感器、其制备方法及应用,通过将聚二甲苯(Parylene)这种材料应用于凝血时间检测,从而增强压电薄膜传感器性能(信噪比、特异性、重复性)的表面修饰方法,以解决现有技术中压电薄膜传感器在检测凝血过程中受到非特异性吸附干扰导致芯片检测频率不稳定、检测时间长等问题。In view of the technical problems existing in the prior art, this case provides a coagulation detection sensor based on hydrophobic modification, its preparation method and application. By applying the material of parylene (Parylene) to the detection of coagulation time, the piezoelectric film is strengthened The surface modification method of sensor performance (signal-to-noise ratio, specificity, repeatability) to solve the problem of unstable detection frequency and long detection time of the chip caused by non-specific adsorption interference in the detection process of blood coagulation in the piezoelectric film sensor in the prior art .
为实现上述目的,本案通过以下技术方案实现:In order to achieve the above purpose, this case is realized through the following technical solutions:
一种凝血检测传感器,其包括有压电薄膜传感器,在该压电薄膜传感器表面修饰有疏水层,所述疏水层为聚二甲苯。A blood coagulation detection sensor includes a piezoelectric thin film sensor, and a hydrophobic layer is modified on the surface of the piezoelectric thin film sensor, and the hydrophobic layer is polyxylene.
优选的是,所述的凝血检测传感器,其中,所述疏水层的厚度为100-1500nm。Preferably, in the coagulation detection sensor, the thickness of the hydrophobic layer is 100-1500 nm.
一种凝血检测传感器的制备方法,其采用真空蒸镀将疏水层镀于压电薄膜传感器表面,所述疏水层为聚二甲苯。A method for preparing a blood coagulation detection sensor, which uses vacuum evaporation to plate a hydrophobic layer on the surface of a piezoelectric film sensor, and the hydrophobic layer is polyxylene.
优选的是,所述的凝血检测传感器的制备方法,其中,所述疏水层的厚度为100-1500nm。Preferably, in the preparation method of the blood coagulation detection sensor, the thickness of the hydrophobic layer is 100-1500 nm.
一种如上所述的凝血检测传感器在对血清样品进行凝血检测中的应用。An application of the coagulation detection sensor as described above in blood coagulation detection of serum samples.
一种如上所述的凝血检测传感器在对全血样品进行凝血检测中的应用。An application of the coagulation detection sensor as described above in coagulation detection of whole blood samples.
本发明的有益效果是:The beneficial effects of the present invention are:
(1)为了解决将凝血产生纤维蛋白吸附到压电薄膜传感器表面的问题,首次将Parylene真空蒸镀到压电薄膜传感器表面,实现表面疏水性的提高,达到了吸附纤维蛋白疏水结构域的效果。(1) In order to solve the problem of adsorbing fibrin produced by blood coagulation to the surface of the piezoelectric film sensor, Parylene was vacuum evaporated on the surface of the piezoelectric film sensor for the first time to improve the hydrophobicity of the surface and achieve the effect of adsorbing the hydrophobic domain of fibrin .
(2)具有良好疏水性纳米级厚度材料Parylene,降低对压电传感器的影响,增强传感器表面与凝血终产物纤维蛋白结合能力,实现提高传感器输出信号频率稳定性的效果。(2) Parylene, a nano-scale thickness material with good hydrophobicity, reduces the impact on the piezoelectric sensor, enhances the binding ability of the sensor surface to the coagulation end product fibrin, and realizes the effect of improving the frequency stability of the sensor output signal.
(3)Parylene本身就是一种耐强酸碱材料,具有优良保护芯片能力。(3) Parylene itself is a strong acid and alkali resistant material, which has excellent ability to protect chips.
(4)Parylene材料具有可批量化修饰的特点,有助于消除芯片修饰批间差异性。(4) The Parylene material can be modified in batches, which helps to eliminate the differences between batches of chip modification.
附图说明Description of drawings
图1为本案Parylene修饰后的传感器芯片检测活化部分凝血活酶时间aPTT检测结果与未修饰Parylene的传感器芯片检测结果对比图。Figure 1 is a comparison chart of the detection results of the activated partial thromboplastin time (aPTT) detected by the sensor chip modified by Parylene in this case and the detection result of the sensor chip of unmodified Parylene.
图2为本案同一Parylene修饰传感器芯片检三次检测同一病人血液样本的结果对比图。Figure 2 is a comparison chart of the results of the same Parylene-modified sensor chip in this case to detect the blood samples of the same patient three times.
图3为本案Parylene修饰后的传感器芯片检测活化部分凝血活酶时间aPTT检测结果与Lambda950紫外分光光度计检测结果对比图。Figure 3 is a comparison chart of the detection results of activated partial thromboplastin time (aPTT) detected by the sensor chip modified by Parylene in this case and the detection results of Lambda950 ultraviolet spectrophotometer.
图4为本案Parylene修饰后的传感器芯片检测活化部分凝血活酶时间aPTT检测结果与Sysmex 2000i检测结果对比图。Figure 4 is a comparison chart of the detection results of activated partial thromboplastin time (aPTT) detected by the sensor chip modified by Parylene in this case and the detection results of Sysmex 2000i.
具体实施方式detailed description
下面结合附图对本发明做进一步的详细说明,以令本领域技术人员参照说明书文字能够据以实施。The present invention will be further described in detail below in conjunction with the accompanying drawings, so that those skilled in the art can implement it with reference to the description.
本案利用真空蒸镀技术将有疏水特性的材料,聚二甲苯(parylene),覆盖在压电薄膜传感器表面,形成一层致密的疏水膜结构,检测凝血时间,包括凝血酶原时间PT、活化部分凝血活酶时间aPTT等。In this case, the material with hydrophobic properties, parylene, is covered on the surface of the piezoelectric thin film sensor by vacuum evaporation technology to form a dense hydrophobic film structure to detect blood clotting time, including prothrombin time PT, activation part Thromboplastin time aPTT and so on.
具体制备过程如下:Parylene(一类物质)固体粉末在150℃、1Torr环境条件下蒸发,在690℃、0.5Torr环境条件下裂解,形成Parylene气态分子,通过疏通管道到达压电薄膜传感器芯片所在的真空反应腔,随着腔室内的温度下降,Parylene气态分子在压电薄膜传感器表面形成一层致密的Parylene疏水膜结构。Parylene修饰后的薄膜压电芯片准备用于凝血时间检测。此外,该修饰技术在真空罐中进行,可批量化操作,易于实现微型化传感技术产品开发及制造。The specific preparation process is as follows: the solid powder of Parylene (a class of substances) is evaporated at 150°C and 1 Torr, and is cracked at 690°C and 0.5 Torr to form Parylene gaseous molecules, which reach the piezoelectric film sensor chip through the dredging pipeline. Vacuum reaction chamber, as the temperature in the chamber drops, Parylene gaseous molecules form a dense Parylene hydrophobic film structure on the surface of the piezoelectric film sensor. The thin-film piezoelectric chip modified by Parylene is ready for blood clotting time detection. In addition, the modification technology is carried out in a vacuum tank, which can be operated in batches, and is easy to realize the development and manufacture of miniaturized sensing technology products.
将芯片置于检测系统中后,用移液枪滴加血液样品和aPTT混合液共100微升,再加入钙离子(50微升)启动凝血反应,凝血终产物纤维蛋白是一种疏水结构蛋白,当凝血结束后,纤维蛋白会交联成网状结构,最大限度暴露其疏水结构域,根据疏水相互作用,该蛋白的疏水结构域会与Parylene修饰形成的疏水表面相互亲和吸附,最终由于粘弹性变化使得压电薄膜传感器表面产生质量变化,从而反应到频率变化,传感信号传输到显示屏输出结果。After placing the chip in the detection system, add a total of 100 microliters of the blood sample and aPTT mixture with a pipette gun, and then add calcium ions (50 microliters) to start the coagulation reaction. The end product of coagulation, fibrin, is a hydrophobic structural protein , when the coagulation is over, the fibrin will be cross-linked into a network structure to expose its hydrophobic domain to the maximum extent. According to the hydrophobic interaction, the hydrophobic domain of the protein will be adsorbed with the hydrophobic surface formed by Parylene modification, and finally due to The change of viscoelasticity causes the quality change on the surface of the piezoelectric film sensor, which responds to the frequency change, and the sensing signal is transmitted to the display screen to output the result.
如图1所示,没有添加血浆或全血的阴性实验结果(曲线1)不会产生明显频率下降,这是由于没有纤维蛋白吸附到传感器表面。未经修饰的压电薄膜芯片的两次aPTT测试结果(曲线2)显示出明显的频率抖动,这是由于纤维蛋白与表面结合不牢固,漂浮于液相中引起的。Parylene修饰芯片凝血时间测试结果(曲线3)与曲线2形成鲜明对比,稳定性得到明显提高,这受益于疏水修饰后传感器表面对纤维蛋白特异性提高。另外,由于未经修饰的芯片检测结果(曲线2)的频率抖动(见曲线2尾部),实验很难有重复性可言。As shown in Figure 1, a negative experiment without the addition of plasma or whole blood (curve 1) does not produce a significant frequency drop due to the absence of fibrin adsorption to the sensor surface. The two aPTT test results (curve 2) of the unmodified piezoelectric film chip show obvious frequency jitter, which is caused by the fibrin not firmly bound to the surface and floating in the liquid phase. The coagulation time test results of the Parylene modified chip (curve 3) are in sharp contrast to curve 2, and the stability is significantly improved, which benefits from the improvement of the specificity of the sensor surface to fibrin after hydrophobic modification. In addition, due to the frequency jitter (see the end of curve 2) of the unmodified chip detection result (curve 2), it is difficult to have repeatability of the experiment.
如图2所示,经过修饰后的芯片检测同一样本凝血时间的三条曲线体现出良好重复性,一方面是由于Parylene形成的疏水表面对纤维蛋白特异性提高,另一方面是因为Parylene材料有很好的生物相容性,仅需要清水冲洗就可再次检测,且批间差异小。As shown in Figure 2, the three curves of the coagulation time of the same sample detected by the modified chip show good repeatability. On the one hand, it is because the hydrophobic surface formed by Parylene improves the specificity of fibrin; on the other hand, it is because Parylene material has a strong Good biocompatibility, it can be tested again only after washing with water, and the difference between batches is small.
如图3所示,光学标准检查aPTT曲线1和Parylene修饰后的芯片检测aPTT曲线2,对应的凝血时间点(位置3)吻合良好,证明了该方案与标准检测方法(YY/T0659-2008)结果一致。As shown in Figure 3, the optical standard inspection aPTT curve 1 and the Parylene-modified chip detection aPTT curve 2, the corresponding coagulation time point (position 3) is in good agreement, which proves that this scheme is consistent with the standard detection method (YY/T0659-2008) The results were consistent.
如图4所示,此为Parylene修饰后的芯片检测aPTT结果与临床检测仪器Sysmex2000i aPTT检测结果线性关系对比图,它表明Parylene修饰后的QCM芯片与现有临床设备的测试结果高度吻合,可以作为医疗仪器设备用于临床医学的aPTT检测。As shown in Figure 4, this is a comparison chart of the linear relationship between the aPTT results of the Parylene-modified chip and the clinical testing instrument Sysmex2000i aPTT. It shows that the Parylene-modified QCM chip is highly consistent with the test results of existing clinical equipment and can be used as Medical instruments and equipment are used for aPTT detection in clinical medicine.
尽管本发明的实施方案已公开如上,但其并不仅仅限于说明书和实施方式中所列运用,它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地实现另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下,本发明并不限于特定的细节和这里示出与描述的图例。Although the embodiment of the present invention has been disclosed as above, it is not limited to the use listed in the specification and implementation, it can be applied to various fields suitable for the present invention, and it can be easily understood by those skilled in the art Therefore, the invention is not limited to the specific details and examples shown and described herein without departing from the general concept defined by the claims and their equivalents.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611112697.7A CN106596642A (en) | 2016-12-06 | 2016-12-06 | Hydrophobic modification based blood coagulation sensor, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611112697.7A CN106596642A (en) | 2016-12-06 | 2016-12-06 | Hydrophobic modification based blood coagulation sensor, preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106596642A true CN106596642A (en) | 2017-04-26 |
Family
ID=58597198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611112697.7A Pending CN106596642A (en) | 2016-12-06 | 2016-12-06 | Hydrophobic modification based blood coagulation sensor, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106596642A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107024509A (en) * | 2017-05-15 | 2017-08-08 | 中国科学院苏州生物医学工程技术研究所 | A kind of preparation method of blood coagulation test paper and its piezoelectric transducer chip |
CN107991385A (en) * | 2017-11-28 | 2018-05-04 | 中国科学院苏州生物医学工程技术研究所 | A kind of method and device in definite clotting time |
CN108414571A (en) * | 2018-02-11 | 2018-08-17 | 中国科学院苏州生物医学工程技术研究所 | Clotting time detection method and device |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200532B1 (en) * | 1998-11-20 | 2001-03-13 | Akzo Nobel Nv | Devices and method for performing blood coagulation assays by piezoelectric sensing |
CN1309776A (en) * | 1998-06-18 | 2001-08-22 | 浜松光子学株式会社 | Method of organic film deposition |
WO2002093168A1 (en) * | 2001-05-15 | 2002-11-21 | Gradipore Limited | Prion diagnostic test |
CN102332529A (en) * | 2011-09-20 | 2012-01-25 | 上海交通大学 | Piezoelectric energy harvester with flexible substrate and preparation method thereof |
CN102370476A (en) * | 2011-09-28 | 2012-03-14 | 上海交通大学 | Cardiovascular blood flow velocity sensor |
KR20130041454A (en) * | 2011-10-17 | 2013-04-25 | 연세대학교 산학협력단 | Apparatus for coating parylene thin film and method for coating parylene thin film using the apparatus |
-
2016
- 2016-12-06 CN CN201611112697.7A patent/CN106596642A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1309776A (en) * | 1998-06-18 | 2001-08-22 | 浜松光子学株式会社 | Method of organic film deposition |
US6200532B1 (en) * | 1998-11-20 | 2001-03-13 | Akzo Nobel Nv | Devices and method for performing blood coagulation assays by piezoelectric sensing |
WO2002093168A1 (en) * | 2001-05-15 | 2002-11-21 | Gradipore Limited | Prion diagnostic test |
CN102332529A (en) * | 2011-09-20 | 2012-01-25 | 上海交通大学 | Piezoelectric energy harvester with flexible substrate and preparation method thereof |
CN102370476A (en) * | 2011-09-28 | 2012-03-14 | 上海交通大学 | Cardiovascular blood flow velocity sensor |
KR20130041454A (en) * | 2011-10-17 | 2013-04-25 | 연세대학교 산학협력단 | Apparatus for coating parylene thin film and method for coating parylene thin film using the apparatus |
Non-Patent Citations (5)
Title |
---|
H. HAN ET AL.: "Application of parylene-coated quartz crystal microbalance for on-line real-time detection of microbial populations", 《BIOSENSORS AND BIOELECTRONICS》 * |
K. EVANS-NGUYEN ET AL.: "Changes in absorbed fibrinogen upon conversion to fibrin", 《LANGMUIR》 * |
K. MEURS ET AL.: "《ECMO:危重病体体外心肺支持》", 31 March 2011, 中国环境出版社 * |
薛巍 等: "《生物医用水凝胶》", 31 December 2012, 暨南大学出版社 * |
黄红军 等: "《金属表面处理与防护技术》", 31 October 2011, 冶金工业出版社 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107024509A (en) * | 2017-05-15 | 2017-08-08 | 中国科学院苏州生物医学工程技术研究所 | A kind of preparation method of blood coagulation test paper and its piezoelectric transducer chip |
WO2018209923A1 (en) * | 2017-05-15 | 2018-11-22 | 中国科学院苏州生物医学工程技术研究所 | Clotting test paper and method for preparing piezoelectric sensor chip thereof |
CN107991385A (en) * | 2017-11-28 | 2018-05-04 | 中国科学院苏州生物医学工程技术研究所 | A kind of method and device in definite clotting time |
WO2019104754A1 (en) * | 2017-11-28 | 2019-06-06 | 中国科学院苏州生物医学工程技术研究所 | Method and device for determining blood coagulation time |
CN107991385B (en) * | 2017-11-28 | 2020-05-22 | 中国科学院苏州生物医学工程技术研究所 | Method and device for determining blood coagulation time |
CN108414571A (en) * | 2018-02-11 | 2018-08-17 | 中国科学院苏州生物医学工程技术研究所 | Clotting time detection method and device |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | A sensitive label-free immunosensor for detection α-Fetoprotein in whole blood based on anticoagulating magnetic nanoparticles | |
Jandas et al. | Highly selective and label-free Love-mode surface acoustic wave biosensor for carcinoembryonic antigen detection using a self-assembled monolayer bioreceptor | |
CN106662539B (en) | Sensors and devices for detecting analytes in liquids | |
CN103837523B (en) | A kind of method detecting orthene and test kit | |
US20120208296A1 (en) | Detection of different target components by cluster formation | |
CN108152512A (en) | Heparin-binding protein detection kit and preparation method thereof | |
CN106596642A (en) | Hydrophobic modification based blood coagulation sensor, preparation method and application thereof | |
CN105785043A (en) | Kit for quantitatively detecting AFP-L3% | |
Kim et al. | Label-free quantitative immunoassay of fibrinogen in alzheimer disease patient plasma using fiber optical surface plasmon resonance | |
Zhang et al. | A miniaturized immunosensor platform for automatic detection of carcinoembryonic antigen in EBC | |
Hussain et al. | Blood coagulation thromboplastine time measurements on a nanoparticle coated quartz crystal microbalance biosensor in excellent agreement with standard clinical methods | |
WO2011093459A1 (en) | HUMAN sCD14-ST ASSAY METHOD | |
CN107044977A (en) | A kind of tyrosine phosphatase antibody chemical luminescence immunity detection reagent and preparation method thereof | |
WO2006118195A1 (en) | Method of immunologically analyzing plasmin degradation product of stabilized fibrin | |
CN104741156B (en) | Platelet screening chip and preparation method thereof and application | |
CN103499692A (en) | Quantitative determination kit for Golgi protease GP73 and detection method thereof | |
JP4996579B2 (en) | Methods for biomolecule immobilization | |
CN101046479B (en) | Process of preparing human serum base matter containing no target protein | |
WO2018000899A1 (en) | Anti-β2 glycoprotein i antibody igg chemiluminescence immunoassay kit and preparation method thereof | |
Wei et al. | Label-free detection of pepsinogen 1 and 2 by polyethylene coating Lamb microfluidic device | |
CN106124776A (en) | CA724 chemiluminescence immune detection reagent kit and preparation method thereof | |
CN205015274U (en) | Molecular dynamics test platform based on reputation allies oneself with to be used | |
CN101639444A (en) | Method for nano particle reinforced fluorescence polarization analysis | |
CN106198959A (en) | Serum hyaluronic acid chemiluminescence immune detection reagent kit and preparation method thereof | |
Hussain | 'Argatroban'Monitoring in Human Plasma: aPTT and PiCT Studies on QCM-D vs' Gold Standard' |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |